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Mitochondria are organelles that are essential for aero-
bic generation of ATP: the molecular currency that pro-
vides the chemical energy to fuel vital cellular processes. 
Mitochondrial number and function decline with normal 
ageing and compromised mitochondrial function is also 
associated with metabolic disorders such as cardio vascular 
disease and type 2 diabetes mellitus (T2DM), as well as 
various types of cancer1–3. Physical activity is probably the 
best-known strategy to improve mitochondrial function 
in metabolically active tissues. Many of the health bene-
fits associated with physical activity might originate from 
exercise-induced improvements in mitochondrial func-
tion4,5. The aim of this Review is to provide an overview of 
human studies targeting mitochondria with the objective 
to improve insulin sensitivity and prevent T2DM.
Insulin resistance
Insulin resistance refers to the blunted response of organs 
to insulin and is an important hallmark of the pathogenesis 
of T2DM. As a compensatory response to insulin resist-
ance, plasma insulin concentrations rise in the early stages 
of T2DM. Insulin-mediated myocellular glucose uptake is 
key to maintaining normal glucose homeostasis, as approx-
imately 80% of postprandial glucose clearance occurs 
within skeletal muscle6. Importantly, circulatory glucose 
levels are also affected by the release of glucose from 
the liver. Hepatic glucose output originates from hydro-
lysis of glycogen (the polysaccharide storage form of 
glucose) in the liver as well as from gluconeogenesis 
(de novo production of glucose from nonglucose-derived 
carbon precursors). Thus, to lower blood glucose levels, 
insulin promotes hepatic uptake of glucose while simul-
taneously inhibiting hepatic glucose production. In addi-
tion, insulin profoundly inhibits adipose tissue lipolysis, 
thereby lowering circulatory levels of fatty acids derived from 
adipose tissue in the postprandial state, which promotes 
the oxidation of glucose over other substrates. For acute 
regulation of glucose homeostasis, the stimulatory effect 
of insulin on glucose disposal and its inhibitory effect on 
hepatic glucose output are most important. However, 
long-term blunted inhibition of adipose tissue lipo lysis 
in the insulin resistant state could result in storage of 
fat in nonadipose tissue and deleteriously affect cell 
function; this process is often referred to as lipotoxicity7.
Insulin resistance and mitochondria
Landmark studies relating insulin resistance to mito-
chondrial dysfunction reported reduced NADH2–O2 
oxidoreductase activity (attributed to complex I) and 
structural mitochondrial aberrations8, with deficiency 
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of subsarcolemmal mitochondrial function9, in patients 
with T2DM compared with healthy controls. Using 
microarray analyses, two independent studies almost 
simultaneously revealed a coordinated downregula-
tion of genes that encode proteins involved in oxidative 
metabolism in muscle biopsy samples from patients 
with T2DM and from individuals with a positive fam-
ily history of T2DM10,11. These downregulated genes are 
under the control of a mitochondrial transcriptional 
cofactor known as peroxisome proliferator-activated 
receptor γ co-activator 1 α (PGC-1α). A series of non-
invasive 31P-magnetic resonance spectroscopy studies in 
elderly (61–84 years) patients12 and in young (26 ± 7 years; 
mean ± SD) insulin-resistant offspring of patients with 
T2DM13 revealed a functional decline in in vivo ATP-
synthase flux, determined by saturation transfer, which 
was identified as evidence for mitochondrial dysfunction. 
However, as mitochondrial activity is driven by cellular 
energy demand, the interpretation that these resting state 
observations truly reflect a mitochondrial defect that 
might contribute to insulin resistance is still subject to 
debate. In addition, from a methodological perspective, 
the interpretation of data from saturation transfer as a 
reflection of the rate of mitochondrial ATP synthesis is 
under discussion, owing to the overestimation of the ATP 
production using this method14. Furthermore, measure-
ments in the resting state are expected to reflect resting 
metabolic rate rather than maximal capacity of mito-
chondrial function. Noninvasive measurement of the 
phosphocreatine resynthesis rate after exercise is used to 
investigate metabolism under stimulated conditions and 
is more widely accepted as a parameter of mitochondrial 
function14. These measurements have revealed that in 
patients with overt T2DM15, as well as in first-degree rela-
tives of patients with T2DM16, muscle oxidative capacity is 
compromised and can precede the development of frank 
T2DM. However, it should be noted that experimental 
animal models designed to directly examine the effect 
of mitochondrial dysfunction on insulin resistance (for 
example, dietary lipid overload17,18 or genetically com-
promised mitochondrial function19), do not necessarily 
show impeded insulin sensitivity. In humans, the debate 
regarding whether mitochondrial dysfunction is causal 
to insulin resistance or is the consequence of sustained 
overnutrition is still ongoing20,21. Notwithstanding this 
debate, multiple lines of evidence indicate that targeting 
mitochondrial biogenesis, structural integrity, function 
and/or number to maintain or improve insulin sensitivity, 
is worth exploring22,23. Of note, biguanides such as met-
formin, which are frequently used as a first-line treatment 
in T2DM, also seem to affect mitochondrial function24–27.
Mitochondrial dysfunction has not been clearly 
defined; in this Review, we refer to all aspects of mito-
chondrial dysfunction, including intrinsic mitochon-
drial dysfunction (characterized by the maintenance 
of mitochondrial mass but a decline in function of iso-
lated mitochondria), reduced oxidative capacity and 
reduced mitochondrial mass.
Metabolic flexibility. How mitochondrial dysfunction 
could be causally linked to compromised insulin sen-
sitivity remains to be determined. Although the most 
established feature of muscle mitochondria is the oxi-
dative generation of ATP to fuel contractile activity of 
muscle fibres and intracellular signal transduction, details 
on quality control of mitochondria and mitochondrial 
maintenance of cellular and organelle function through 
processes such as autophagy or mitophagy were only 
described in the past few years28,29. Aberrations in auto-
phagy and mitophagy have also been implicated in the 
aetiology of T2DM30. To adapt to oscillations in energy 
demand and substrate availability, healthy mitochondria 
can switch readily between oxidative metabolism of fatty 
acids and glucose. Although glucose can also be used to 
generate ATP nonoxidatively, catabolism of fatty acids 
requires proper mitochondrial function; therefore, if 
functional mitochondria are few and supply of glucose 
is sufficient (such as in the postprandial state), fatty acids 
compete with glucose for oxidative degradation31. With 
a reduced number of functional mitochondria, the flex-
ibility to adjust substrate oxidation to substrate supply 
is diminished, a phenomenon referred to as metabolic 
inflexibility32. Indeed, the inflexibility to adapt substrate 
selection from predominantly fatty acids in the fasted state 
to glucose oxidation in the postprandial, high-insulin 
state is a common characteristic of insulin-resistant 
muscle33 and is often observed in conjunction with 
mitochondrial dysfunction in patients with T2DM.
At the cellular level, metabolic flexibility can be 
explained by the competition of acetyl coenzyme A 
(acetyl-CoA) derived from glycolysis or from β-oxidation 
for entrance into the tricarboxylic acid cycle; accumu-
lation of acetyl-CoA, for example derived from high 
β-oxidation fluxes, can inhibit pyruvate dehydrogenase 
activity and reduce glycolytic flux (FIG. 1). In an attempt to 
maintain low mitochondrial acetyl-CoA levels and to sus-
tain glycolytic flux, acetyl-CoA can be converted to acetyl-
carnitine by the mitochondrial matrix enzyme carnitine 
acetyltransferase (CrAT). However, in a state of insulin 
resistance, the availability of free carnitine is decreased34 
and the activity of CrAT is hampered35. In patients with 
obesity or T2DM, acetylcarnitine levels are low and CrAT 
activity correlates strongly and positively with insulin sen-
sitivity36. This mechanism might underlie compromised 
postprandial glucose oxidation in the insulin resistant 
Key points
• Type 2 diabetes mellitus (T2DM) is associated with reduced mitochondrial function 
in the skeletal muscle and metabolic inflexibility
• Healthy mitochondria require a tight balance between mitochondrial biogenesis 
and mitophagy, as well as between mitochondrial ATP and reactive oxygen species 
production
• Exercise training is the intervention that most comprehensively improves the 
diverse aspects of mitochondrial function, along with whole-body and skeletal 
muscle insulin sensitivity
• Calorie restriction and calorie restriction mimetics are strong nonexercise tools to 
boost mitochondrial function, probably via the activation of an AMPK–NAD+–SIRT 
pathway
• Novel environmental and lifestyle factors, such as sleep and ambient temperature, 
might also affect mitochondrial function and insulin sensitivity in humans
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state and aids understanding of the observed metabolic 
inflexibility, as reduced acetylcarnitine production would 
lead to the accumulation of acetyl-CoA and consequently 
inhibit conversion of pyruvate, impeding the use of glu-
cose as a respiratory substrate. Conversely, an abundance 
of mitochondria with high CrAT activity promotes 
acetylcarnitine generation, which enables buffering of 
fluctuations in substrate availability and thereby improves 
metabolic flexibility and glucose tolerance.
Mitochondrial ROS production. Superoxide and other 
reactive oxygen species (ROS) are generated as inevi-
table by-products of mitochondrial respiration. Excess 
ROS production, which could be due to dysfunctional 
mitochondria, in the absence of sufficient antioxidant 
capacity might result in lipid peroxidation and other 
forms of oxidative stress such as damage to nuclear and 
mitochondrial DNA37, which in turn might also directly 
contribute to the development of insulin resistance38.
A high supply of electron donors to the electron 
transport chain without a concomitant increase in ATP 
synthase flux results in a high proton gradient across 
the inner mitochondrial membrane and augments ROS 
production. By adjusting the efficiency of ATP genera-
tion within the mitochondrial machinery, mitochondria 
can regulate cellular energy turnover and superoxide 
production. The underlying process responsible for 
reducing the efficiency of ATP production (and hence 
modulating energy turnover, superoxide production 
and heat production) is referred to as mitochondrial 
uncoupling. Mitochondrial uncoupling can occur in a 
tightly regulated way, for example, uncoupling occurs 
upon cold exposure in brown adipose tissue (BAT) via 
the activation of uncoupling protein 1 (UCP1; BOX 1), 
a transmembrane protein that decreases the proton 
gradient generated through oxidative phosphorylation. 
In other tissues, mitochondria can also be uncoupled 
by fatty acids39, although the exact mechanism is not 
known. However, it remains to be elucidated to what 
extent uncoupling of mitochondria in other cell types 
contributes to regulation of ROS production and/or 
energy turnover. Clearly, mitochondrial efficiency and 
mild uncoupling are attractive therapeutic targets to 
increase energy turnover and alleviate ROS produc-
tion, thereby promoting glucose catabolism and thus 
insulin sensitivity (BOX 1). However, it should be noted 
that uncontrolled uncoupling is an unwanted process 
as it could result in a life-threatening increase in body 
temperature and critically low ATP levels40. 
Mitochondrial health, maintenance and dynamics. 
According to the currently widely supported endosym-
biotic theory, mitochondria in eukaryotic cells originate 
from symbiosis of single-celled organisms and proteo-
bacteria41. Hence, mitochondria carry their own circular 
DNA42 that encodes 22 transfer RNAs and only 13 pro-
teins, some of which are required to maintain respiratory 
activity. A short open reading frame in the mitochondrial 
DNA (mtDNA) has been identified that encodes at least 
two mitochondria-derived signalling peptides that have 
been implicated in insulin resistance: humanin43 and 
mitochondrial-derived peptide MOTS-c44. The majority of 
the mitochondrial proteins are nuclear-encoded and rely 
on post-translational import into the mitochondrion45. 
For nuclear-encoded genes, induction of gene expression, 
protein synthesis, processing and mito chondrial import 
relies on cellular translational machinery, but must occur 
in an orchestrated manner with replication of mtDNA and 
subsequent mitochondrial protein synthesis. This need for 
orchestration is exemplified by the observation that tran-
scription of mtDNA genes requires the nuclear-encoded 
mitochondrial transcription factor A46. 
The master regulator of this complex process is 
PGC-1α, which interacts with a variety of nuclear tran-
scription factors involved in maintenance of the oxidative 
phenotype, such as nuclear hormone receptors, nuclear 
respiratory factors and muscle-specific transcription 
factors. Mice overexpressing PGC-1α have more muscle 
fibres that are dependent on oxidative metabolism and a 
massive increase in mitochondrial mass compared with 
wild-type mice47. Mitochondria isolated from PGC-1α 
overexpressing mice have an increased capacity to oxi-
dize lipids compared with wild-type mice48. Lifelong 
overexpression of PGC-1α in mouse skeletal muscle 
reduces insulin sensitivity49 (unless energy demand is 
increased50); conversely, transfection of human muscle 
cells with PGC-1α yields an insulin-sensitive phenotype 
similar to that which is observed in highly trained athletes, 
with increased mitochondrial number and seques-
tration of excess lipid in inert cellular lipid droplets51. 
Additionally, a number of oxidative genes under control 
Figure 1 | The conversion of acetyl-CoA to 
acetylcarnitine by carnitine-acyltransferase. Excess 
acetyl units can be exported from the mitochondria to 
prevent mitochondrial acetyl-coenzyme A (acetyl-CoA) 
accumulation. Accumulation of acetyl-CoA inhibits 
glucose metabolism by inhibiting pyruvate dehydrogenase 
(PDH), the enzyme that acts as the gate keeper for entry of 
glycolysis-derived pyruvate into the mitochondria and 
hence a key regulator for oxidative glucose degradation. 
By transferring acetyl units to acetyl-carnitine, carni-
tine-acyltransferase (CrAT) alleviates the inhibitory effect 
of excess mitochondrial acetyl-CoA on the flux through the 
PDH complex, facilitating oxidative glucose catabolism. 
TCA, tricarboxylic acid.
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of PGC-1α undergo concerted downregulation in patients 
with increased susceptibility to T2DM10,11. Furthermore, 
insulin sensitizing treatments such as exercise training52 
and rosiglitazone53 result in the parallel restoration of 
both PGC-1α and insulin sensitivity, which suggests 
that PGC-1α is an important therapeutic target for the 
improvement of mitochondrial function and insulin sen-
sitivity. Interestingly, phosphorylation and deacetylation 
of PGC-1α both regulate its activity. Although phos-
phorylation of PGC-1α seems to be mediated by AMP 
activated protein kinase (AMPK), which is activated by 
a drop in the ATP:AMP ratio, deacetylation depends 
on NAD+-mediated activation of NAD-dependent pro-
tein deacetylase sirtuin-1 (SIRT1)54, both of which are 
factors that have been associated with improved insulin 
sensitivity.
Downstream of PGC-1α and other members of 
the PGC1 transcription family, activation of a pro-
tein involved in regulating mitochondrial turnover, 
mitofusin-2, maintains the mitochondrial network55, 
which is a process that is also sensitive to metabolic 
perturbations. Although mitochondria are classically 
portrayed as solitary organelles, mitochondria present 
as a network of interconnected organelles in very large, 
metabolically dynamic cells such as those of the skeletal 
muscle. The network facilitates transmission of oxygen 
from the capillaries to the core of the myocyte (FIG. 2a) 
and creates electrical connectivity for rapid conduct-
ance of mitochondrial membrane potential56 through-
out the lengthy muscle cells (FIG. 2b). Maintenance of the 
mitochondrial network requires a constant antagonist 
balance between mitochondrial fusion and fission57, 
collectively referred to as mitochondrial dynamics. 
These dynamics are essential for quality control of 
mitochondria. Using mitochondrial fusion, damaged 
mtDNA is exchanged with intact mtDNA from neigh-
bouring mitochondria. Conversely, mitochondrial 
fission enables the removal of impaired or redundant 
mitochondria by an autophagic process referred to as 
mitophagy, thus preventing proliferation of mutated 
mtDNA57.
Dynamics of mitochondria could also have a role in 
the acute regulation of the efficiency of mitochondrial 
ATP generation. Mitochondrial fusion encompasses 
fusion of the outer mitochondrial membrane, regulated 
by mitofusin-1 and mitofusin-2, and fusion of the inner 
mitochondrial membrane, regulated by dynamin-like 
120 kDa protein (also known as optic atrophy protein 1; 
OPA1)58. Mitochondrial fusion achieved by induction of 
mitofusin-2 is transiently triggered upon either absolute 
nutrient deprivation, indicated by a cellular drop in ATP 
levels, or by relative nutrient deprivation, characterized 
by increased demand for ATP generation59,60. Under 
these conditions, OPA1 promotes tightening of mito-
chondrial cristae width and assembly of ATP synthase, 
which in turn promotes efficiency of ATP production61. 
Conversely, excess supply of mitochondrial substrate 
increases proton motive force (BOX 2) and promotes 
mitochondrial production of ROS. These circumstances 
trigger mitochondrial fission62 by binding of dynamin- 
1-like protein (DNML1) to its outer membrane receptor 
mitochondrial fission 1 protein (FIS1)63.
The process of mitochondrial fusion has also been 
proposed to lead to mitochondrial uncoupling and 
thereby to dissipation of energy, at least in mouse, 
rat and cell models. In addition, experiments in BAT 
mitochondria have shown that excess nutrient supply 
induces mitochondrial fragmentation, with a conco-
mitant drop in mitochondrial efficiency and increased 
fatty-acid-mediated uncoupling64. Thus, continuous 
oversupply of nutrients might induce fission, which 
— in the absence of opposed fusion — translates into 
mitochondrial uncoupling and energy dissipation 
with increased energy expenditure as a consequence. 
Interestingly, a low metabolic rate in humans, such as 
that detected during sleep, has been associated with the 
development of obesity and metabolic diseases; skeletal 
muscle is considered to be a major determinant of human 
resting metabolic rate65. So far, the processes underlying 
the variability in human energy metabolism have not 
been revealed, although the discovery of UCP3, a hom-
ologue of UCP1, in human skeletal muscle resulted in 
speculations that these inner mito chondrial membrane 
proteins might be responsible for the variation in meta-
bolic rate66. However, no evidence is currently available to 
suggest that these uncoupling proteins can be considered 
direct determinants of human metabolic rate.
To speculate that the dynamic process of mitochondrial 
fusion and fission might underlie some of the variance in 
human metabolic rate is tempting. Under conditions of 
transiently increased energy demand, fusion generates a 
mitochondrial network that is well equipped for efficient 
ATP generation while simultaneously providing means 
to maintain mtDNA quality. Under conditions of a tran-
sient energy oversupply, mitochondrial fission renders 
mitochondria inefficient and excess substrates can be 
consumed as a counterbalance response, while simulta-
neously relieving ROS production. Disturbances in this 
process of mitochondrial dynamics might, therefore, 
Box 1 | Mitochondrial uncoupling 
Mitochondrial uncoupling is the process by which the proton motive force built up by 
the electron transport chain is uncoupled from oxidative phosphorylation by proton 
leak or by uncoupling proteins in the inner mitochondrial membrane. In brown adipose 
tissue, this process is tightly regulated and facilitated by uncoupling protein 1, which is 
specific for brown and beige adipocytes. Regulated mitochondrial uncoupling by 
uncoupling proteins dissipates the proton gradient to generate heat rather than ATP 
and is, therefore, suggested to be involved in the regulation of body temperature. In 
other tissues, uncoupling proteins are also present but might have distinct functions. 
Thus, in the case of excess substrate availability, the supply of NADH or FADH2 to the 
electron transport chain is increased and hence the proton gradient is heightened. If 
cells are inactive and ADP levels and ATP turnover are low, then proton motive force is 
not dissipated by the ATP synthase but by proton leak only; thus, electron flow through 
the electron transport chain is substantially reduced, whereas the proton motive force 
is high. Under these conditions, the electrons donated to O2 result in generation of 
superoxide and H2O2, which results in a condition of oxidative stress. Modest 
mitochondrial leak or mild mitochondrial uncoupling via uncoupling proteins such as 
uncoupling protein 3 can dissipate the proton motive force and hence serve to alleviate 
oxidative stress159. In most cell types, coupling of mitochondria is not 100% efficient but 
ranges between 70% and 90% and the relationship between proton motive force and 
superoxide production is fairly steep. Thus, mild uncoupling can be a tool to alleviate 
oxidative stress at the expense of bioenergetic efficiency160.
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limit the regulation of mitochondrial ATP efficiency and 
dissipation of excess energy as well as disrupting the qual-
ity control of mitochondria. As a result of these changes, 
mitophagy will be promoted, and mitochondrial content 
and function might become compromised67. Indeed, 
sustained defects in mito chondrial dynamics can com-
promise mitochondrial quality and are associated with 
insulin resistance; furthermore, studies in mice and in rat 
muscle cells have revealed that repression of mitofusin-2 
expression reduced glucose oxidation and impaired 
glucose homeostasis68.
Conversely, mitofusin-2 gain-of-function experi-
ments in cell models showed an abundance of perinuclear 
mitochondria and enhanced glucose oxidation69. A 
defect in mitofusin-2 is, however, not causally linked to 
insulin resistance, as is exemplified by the observation 
that humans carrying a defect in the gene that encodes 
mitofusin-2 (resulting in a neurodegenerative disorder 
known as Charcot–Marie–Tooth disease) are not chara-
c terized by aberrant glucose handling or insulin resist-
ance70. Expression of mitofusin-2 in skeletal muscle is 
lowered in patients with obesity and T2DM; moreover, 
mitofusin-2 expression levels correlated positively with 
insulin sensitivity in patients with T2DM. This finding 
indicates that induction of mitofusin-2 could promote 
mitochondrial fusion in order to surmount increases in 
fission mediated by the oversupply of nutrients, maintain-
ing or improving insulin sensitivity as a consequence71. 
Induction of mitochondrial fission by nutrient oversup-
ply promotes mitochondrial dysfunction and has been 
causally linked to insulin resistance in C2C12 skeletal 
muscle cells as well as in H9c2 cardiac myocytes72,73. So far, 
non-lethal mutations in genes involved in mitochondrial 
fission have not been identified74; hence, data in humans 
on the role of mitochondrial fission and insulin resist-
ance is lacking, but sustained disturbances in the delicate 
balance of fission and fusion could feasibly impede 
mitochondrial quality control and respiratory capacity.
Although these data do not presently reveal a unifying 
mechanism that links mitochondrial function to insulin 
sensitivity, it seems safe to state that by targeting meta-
bolic flexibility, ROS stress and mitochondrial quality 
control (through the balancing of mitochondrial bio-
genesis, autophagy, mitophagy, fission and fusion), 
aspects of mitochondrial function can be improved, all 
of which are linked to insulin sensitivity.
Effects of exercise
Exercise training is one of the most potent ways to 
promote increased muscle oxidative capacity, and is 
considered one of the best strategies to prevent and treat 
T2DM. A pioneering study in the early 1980s showed 
that a training programme of 16 weeks improved periph-
eral insulin sensitivity in human muscle of insulin resist-
ant patients with type 1 diabetes mellitus in parallel with 
increased mitochondrial oxidative enzyme capacity75, 
preceding the discovery of the exercise responsive solute 
carrier family 2, facilitated glucose transporter member 4 
(GLUT-4) in 1987 (REF. 76). A plethora of papers have 
examined the effect of a wide range of exercise training 
programmes on markers of mitochondrial function 
and insulin sensitivity in humans52,77–86. Although these 
studies consistently report exercise-mediated improve-
ments in mitochondrial function and insulin sensitivity 
(TABLE 1), it is also clear that a mutual improvement in 
both of these factors is not necessarily guaranteed.
One potential confounder contributing to the dis-
sociation between improvements in mitochondrial 
function and improved insulin sensitivity is the dura-
tion of T2DM at the time of intervention. Indeed, it was 
observed that baseline maximal oxygen consumption 
correlates inversely with the duration of T2DM87. In 
addition, an increase in mitochondrial function upon 
treatment with the insulin-sensitizing drug rosiglita-
zone, which was measured by the increase in expres-
sion of proteins in the electron transport chain and 
increased citrate synthase activity, was only observed in 
patients with the best preserved basal aerobic capacity87. 
However, whether this outcome also applies to exercise- 
induced effects on mitochondrial function is presently 
unknown. In a short-term high intensity training pro-
gramme, mitochondrial function improved similarly 
in individuals without T2DM and in the offspring of 
mothers with T2DM, whereas insulin sensitivity 
improved only in people without diabetes mellitus84. 
A more classic endurance type of training programme, 
consisting of three 20–35 min sessions of cycling exer-
cise per week for 10 weeks, in patients with T2DM and 
BMI-matched normoglycaemic controls also improved 
mitochondrial function, but these changes were not 
quantitatively correlated with improvements in insulin 
sensitivity82.
Another reason for this apparent lack of correlation 
between changes in mitochondrial function and insulin 
sensitivity might originate from the definition of insu-
lin sensitivity, which consists of oxidative (stimulation of 
glucose oxidation by insulin) and nonoxidative (stimu-
lation of glycogen storage by insulin) insulin-stimulated 
glucose uptake. Thus, in a training study in patients with 
Figure 2 | Mitochondrial network morphology. a | Cross-sectional transmission 
electron micrograph of a skeletal muscle cell in a rat soleus muscle showing penetration 
of a mitochondrial network (black arrows) from the site of oxygen and substrate supply 
(the capillaries, grey arrows) towards the core of the muscle cell. Scale bar represents 
20 μm. b | Confocal microscopy image of the extension of the mitochondrial network 
along cultured human myotubes, taken in the longitudinal plane. The mitochondrial 
network was visualized by staining against mitochondrial import receptor subunit 
TOM20 homologue. The signal is pseudocoloured in red, areas with high mitochondrial 
density display orange and yellow. Scale bar represents 20 μm.
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T2DM and normoglycaemic controls matched for BMI, 
age and physical fitness, our group observed that train-
ing increased protein expression of electron transport 
chain complex I–V, and ADP-driven state 3 respiration 
(mitochondrial oxygen consumption upon the addition 
of substrates and ADP) on a variety of substrates, such as 
glutamate and succinate, and also improved phospho-
creatine recovery rate after exercise in both groups. In 
patients with T2DM, we detected restoration of mito-
chondrial function to levels observed in normoglycaemic 
control individuals52,86. Interestingly, dissecting oxidative 
from nonoxidative glucose disposal revealed that oxida-
tive glucose disposal was restored to control values, in 
line with restoration of mitochondrial function, whereas 
nonoxidative glucose disposal was not restored52. This 
observation indicates that an exercise-induced improve-
ment in mitochondrial function improves the oxidative 
part of insulin sensitivity, but not necessarily the non-
oxidative part, and thereby aids our understanding of 
the reported dissociation between training-mediated 
improvements in mitochondrial function and insulin 
sensitivity observed in some studies. Notably, metabolic 
flexibility, which has also been hypothesized as a putative 
mechanism connecting mitochondrial dysfunction and 
insulin resistance, was similarly restored upon exercise 
training in this particular study52. Training-mediated 
improvements in metabolic flexibility and concomi-
tant improvements in insulin sensitivity have also been 
observed in patients with impaired fasting glucose 
and impaired glucose tolerance88, which suggests that 
improving metabolic flexibility by physical activity 
can be beneficial in preventing the transition from an 
impaired glucose tolerant to an insulin resistant state. 
Encouragingly, metabolic flexibility and markers of 
mitochondrial function were both shown to correlate 
with levels of habitual physical activity89,90. This finding 
endorses the feasibility of targeting metabolic flexibil-
ity by promoting habitual physical activity to improve 
insulin sensitivity.
Alternatively, exercise training could affect insulin 
sensitivity via alteration of mitochondrial ROS produc-
tion. In healthy women, an 8-week exercise training 
programme improved insulin sensitivity, as defined by 
HOMA, and the balance of oxidative stress markers to 
antioxidant status markers also improved91. In addition, 
women with insulin resistance and polycystic ovary syn-
drome who underwent a 12-week endurance training 
programme had reduced mitochondrial H2O2 produc-
tion, increased catalase activity and reduced oxidative 
DNA damage subsequent to the training programme, 
in parallel with improvements in insulin sensitivity92. 
An interesting mechanistic explanation for how exer-
cise training might alleviate H2O2 production in diabetic 
muscle is provided by studies showing that the bioactive 
lipid derivative palmitoyl coenzyme A (palmitoyl-CoA) 
diminishes mitochondrial influx of ADP in human 
diabetic muscle93. As a result of this inhibition of ADP 
transport, dissipation of the proton motive force via ATP 
synthesis is reduced, with increased H2O2 production as 
a consequence. Interestingly, exercise training reduces 
the inhibitory effect of palmitoyl-CoA on mitochondrial 
ADP influx, thereby promoting ATP synthesis with con-
comitant reduction of proton motive force and alleviation 
of oxidative stress93. ADP/ATP translocase 1, a mitochon-
drial protein that is extensively acetylated in human 
diabetic muscle, facilitates mitochondrial ADP–ATP 
exchange and hence the capacity of ATP synthase to dis-
sipate the proton gradient and alleviate oxidative stress94. 
Interestingly, the level of acetylation of mitochondrial 
proteins is negatively correlated with glucose disposal 
rates, whereas exercise-induced reduction of ADP/ATP 
translocase 1 acetylation correlates with improvements 
in glucose disposal94. Moreover, our group found that 
ADP/ATP translocase 1 protein expression and the sensi-
tivity of ADP/ATP translocase 1 to fatty acids resulting in 
fatty-acid-induced uncoupling was heightened in trained 
athletes compared with lean, sedentary controls, and 
correlated with glucose disposal95. Interestingly, using a 
noninvasive NMR-based approach to calculate the ratio 
of ATP synthesis to tricarboxylic acid cycle flux in skel-
etal muscle as a measure of mitochondrial coupling effi-
ciency in trained athletes showed elevated mitochondrial 
uncoupling in exercise-trained muscle96. Although direct 
evidence that exercise training alleviates ROS produc-
tion and thereby promotes insulin sensitivity is limited, 
these studies suggest that the beneficial effects of exercise 
on insulin sensitivity can also be linked with exercise- 
mediated improvements in respiratory substrate han-
dling that alleviates ROS production via regulated 
mitochondrial energy dissipation (BOX 2).
Data from animal studies have revealed that targeting 
mitochondrial dynamics by exercise training could lead 
to profound mitochondrial remodelling97. However, only 
a few human studies have examined the effect of exercise 
Box 2 | Mitochondrial energy production
The primary task of skeletal muscle mitochondria is to generate ATP. To do so, 
mitochondria need reducing equivalents (such as NADH and FADH2) and O2. Reducing 
equivalents predominantly originate from the catabolism of glucose and fatty acids by 
glycolysis, β-oxidation and the tricarboxylic acid cycle. Mitochondrial ATP generation 
requires potential energy for the reaction of inorganic phosphate with ADP to 
generate ATP and H2O. The potential energy is derived from building a proton gradient 
across the inner mitochondrial membrane by the electron transport chain. In the 
electron transport chain, NADH is reduced by complex I (also known as NADH 
dehydrogenase). Complex I facilitates pumping of protons across the inner 
mitochondrial membrane and transfers electrons to coenzyme Q. Complex II (also 
known as succinate dehydrogenase) and the ubiquinone–coenzyme Q cycle transfers 
electrons from FADH2, which can originate from tricarboxylic acid cycling, as well as 
from anaplerotic reactions (chemical reactions that form intermediates of a metabolic 
pathway) of amino-acid-derived carbons such as succinyl-coenzyme A into succinate 
dehydrogenase. Complex II has no proton pumping capacity. Complex III has proton 
pumping capacity and contains the ultimate electron acceptor cytochrome C. 
Complex IV (also known as cytochrome C oxidase) also pumps protons across the 
inner mitochondrial membrane upon acceptance of the electrons offered by 
cytochrome C. The activity of complex IV is dependent on O2, as O2 is the final electron 
acceptor. In the presence of hydrogen and upon acceptance of two electrons, O2 is 
reduced to H2O at complex IV. As the permeability of the intact inner mitochondrial 
membrane for protons is minimal, proton pumping results in a proton gradient and 
hence increases proton motive force across the membrane. In skeletal muscle 
mitochondria, a protein complex that spans the inner mitochondrial membrane, 
complex V (also known as ATP synthase), utilizes energy from the proton gradient to 
catalyse ATP production and drive the high ATP:ADP ratio in cells. This process of 
oxidative phosphorylation is driven by high ATP turnover.
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training on mitochondrial dynamics and its putative 
relationship with insulin sensitivity. In trained cyclists, 
acute exercise induces increased expression of genes that 
encode proteins involved in mitochondrial dynamics, 
such as mitofusin-1 and mitofusin-2 (REF. 98). In healthy 
sedentary patients, as well as in patients with chronic heart 
failure, endurance training induced increased expres-
sion of genes involved in mitochondrial fusion (such 
as the gene that encodes mitofusin-2) and fission (such as 
the gene that encodes DNML1)99, which is suggestive of 
training-mediated activation of mitochondrial remodel-
ling (although this process was not directly measured). 
In patients newly diagnosed with T2DM, baseline gene 
expression of markers of mitochondrial dynamics are 
reduced compared with control individuals with obesity. 
However, only individuals with obesity and not patients 
with T2DM responded to exercise training, with improve-
ments in the mitochondrial remodelling machinery100. 
At present, the only study linking exercise-mediated 
changes in mitochondrial dynamics to markers of insulin 
sensitivity was performed in adults with insulin resist-
ance and obesity, and showed that exercise training 
reduced phosphorylation of DNML1 (thereby inhibiting 
fission) whereas markers of mitochondrial fusion (such 
as mitofusin-1, mitofusin-2 and OPA1) showed a trend 
towards elevation. Moreover, the reduction in DNML1- 
mediated fission activity correlated with the training- 
mediated improvement in insulin sensitivity101. Thus, 
although conceptually attractive and supported by ani-
mal data, the notion that mitochondrial remodelling 
upon exercise training might contribute to improved 
mitochondrial function and insulin resistance remains 
to be firmly supported by experimental data in humans.
Nonexercise mediated effects
In addition to the well-known effects of exercise on 
mitochondrial function, studies in the past two decades 
have also investigated nonexercise means to promote 
many aspects of mitochondrial function. Although the 
number of suggestions for putative targets to modulate 
Table 1 | Effect of exercise training on mitochondrial function and glucose homeostasis in humans
Study Population Intervention Findings




middle-aged men and women 
with overweight or obesity 
Aerobic exercise training Increased electron transport chain 




Menshikova et al.77 Healthy men and women 
aged 21–87 years
Aerobic exercise training Increased citrate synthase activity, 
cytochrome C oxidase activity and 
mitochondrial gene transcription
Improvement in intravenous 
glucose tolerance test, 
inversely related to age
Short et al.78 Men and women with T2DM Moderate intensity 
exercise training and 
weight loss
Increased mtDNA copy number, 




Toledo et al.79 Sedentary normoglycaemic 
middle-aged men and women 
with overweight or obesity
Moderate or vigorous low 
or high volume exercise 
training
Intensity dependent increase in 




Bajpeyj et al.80 Women with PCOS and 
overweight
Moderate or vigorous 
exercise training
Increase in OXPHOS protein 
content, citrate synthase and HAD
Improved hyperinsulinaemic 
euglycaemic clamp
Hutchison et al.81 Women with T2DM and 
obesity









middle-aged men and women 
with overweight
Low volume interval 
exercise
Increased cytochrome C oxidase 
and citrate synthase protein 
content
Increased GLUT-4 protein 
content and improved 
HOMA
Hood et al.83 Adult normoglycaemic 
first-degree relatives of 
patients with T2DM
Intensive exercise training 
(9 days)
Increase in luciferase-based 
mitochondrial ATP production rate 
and citrate synthase activity
Improved hyperinsulinaemic 
euglycaemic clamp in 
nondiabetic controls but not 
in first-degree relatives of 
patients with T2DM
Irving et al.84 Men and women after RYGB 
surgery
Exercise and weight loss 
after RYGB
Improved mitochondrial 
respirometry and increased 
cardiolipin levels
Improvement in intravenous 
glucose tolerance test
Coen et al.85 Middle-aged men with 
obesity and T2DM






Phielix et al.86 Middle-aged men and women 
with obesity and T2DM
Combined aerobic and 
resistance exercise
Improved phosphocreatine 




GLUT-4, solute carrier family 2, facilitated glucose transporter member 4; HAD, 3-hydroxy-acylCoA-dehydrogenase; mtDNA, mitochondrial DNA; OXPHOS, 
oxidative phosphorylation; PCOS, polycystic ovary syndrome; RYGB, Roux-en-Y gastric bypass; T2DM, type 2 diabetes mellitus.
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mitochondrial function in a nonexercise manner from 
animal studies is high, only a few of these targets have 
been confirmed or studied in humans.
Calorie restriction, NAD+ metabolism and sirtuins. 
In a wide range of species, including humans, cal-
orie restriction is effectively the sole intervention 
with proven effects of promoting increased lifespan. 
Although the underlying mechanisms for these 
calorie-restriction-mediated effects are not completely 
understood, many of the suggested processes involve 
mitochondria102. Investigations in humans, however, 
are limited. Weight loss has been recognized to improve 
insulin sensitivity, but studies examining the effects of 
weight loss often practice a rigid restriction in energy 
intake that is not comparable to the calorie restriction 
regimes performed in other species. One of the best con-
trolled and longest calorie restriction trials in humans, 
featuring a 25% reduction of baseline energy require-
ments, reported reduced fasting insulin levels103 and 
increased gene expression of PGC-1α, mitochondrial 
transcription factor A and SIRT1, along with increased 
mtDNA content in skeletal muscle after calorie restric-
tion104, which indicates that mitochondrial remodelling 
might also be part of the adaptive process to calorie 
restriction in humans. These studies suggest a central 
role for SIRT1 and its activator NAD+ as molecular 
regulators of the beneficial effects of calorie restriction 
and increased insulin sensitivity105.
Profound fluctuations in NAD+ are associated with 
increased energy expenditure (BOX 1). The rate-limiting 
step for the biosynthesis of NAD+ is a reaction catalysed 
by nicotinamide phosphoribosyltransferase (NAMPT). 
Indeed, NAMPT106,107, NAD+, precursors of NAD+ 
(REF. 108) and SIRT1 (REF. 109) have all successfully been 
targeted to promote deacetylase activity and insulin 
sensitivity in animals. Although the gene expression of 
SIRT1 is reduced in patients with T2DM compared with 
healthy individuals110, human intervention studies have 
so far been limited. In addition, a phase II study using 
a novel SIRT1 activator failed to show beneficial effects 
on fasting and postprandial glucose metabolism111. The 
polyphenolic compound resveratrol was identified as 
a small-molecule activator of SIRT1 (REF. 112), and has 
been widely studied in humans, with >10 human clinical 
resveratrol intervention trails performed to date, exam-
ining markers of insulin sensitivity as the primary out-
come113. Although promising results have been obtained, 
the outcomes of these studies are not unequivocal, which 
might originate from differences in duration and dosing 
levels of resveratrol between the trials. Unfortunately, 
only a few human studies have investigated whether 
resveratrol administration results in activation of the 
AMPK–SIRT1 axis114, as was suggested by findings from 
animal model studies. For further discussion on the 
effects of resveratrol on human metabolism we refer 
the reader a previous review115.
In a more direct way to affect mitochondrial meta-
bolism, NAD+ levels could be increased by supplemen-
tation of the natural NAD+ precursor nicotinamide 
riboside. In mice, this approach resulted in improved oxi-
dative capacity and alleviation of high-fat-diet-induced 
meta bolic aberrations116, and both prevented and reverted 
development of nonalcoholic fatty liver disease in mice 
via induction of an imbalance in mitochondrial-encoded 
proteins compared with nuclear-encoded mitochondrial 
proteins in a SIRT1 and SIRT3-dependent manner117. 
The likelihood that nicotinamide riboside supplementa-
tion is also beneficial for humans was underscored by a 
2015 paper that reported ex vivo nicotinamide riboside 
treatment of peripheral blood mononuclear cells from 
healthy volunteers, which revealed increased mitochon-
drial respiratory capacity, increased antioxidant capacity 
and reduced mitochondrial ROS production upon nic-
otinamide riboside treatment118. Furthermore, using an 
indirect approach, our group showed that boosting NAD+ 
levels via the NAD+ precursor acipimox robustly induced 
an imbalance in mitochondrial-encoded and nuclear- 
encoded mitochondrial proteins and improved muscle 
mitochondrial respiration in patients with T2DM119. 
Clearly, more human intervention studies are needed to 
reveal the true potential of targeting the AMPK–NAD+–
SIRT1 pathway (FIG. 3) to improve insulin sensitivity, but 
the data available so far are certainly promising.
Circadian rhythms and sleep. Evidence from epide-
miological120,121 and intervention studies122,123 increas-
ingly implicate a role for circadian rhythms and sleep in 
maintenance of glucose homeostasis. Night shift workers 
(who represent ~10% of the working global population) 
have an increased risk of developing T2DM and cardi-
ovascular disease124. Furthermore, laboratory-induced 
circadian misalignment, caused by 28 h days, results in 
disturbances in glucose homeostasis in healthy individ-
uals123. Most importantly, circadian misalignment not 
only affects a small part of the general population who 
undertake night shifts, but also the larger part of the 
Figure 3 | Schematic overview of the role of NAD+ in the regulation of 
mitochondrial metabolism. Exercise and caloric restriction directly and indirectly 
activate AMPK, thereby activating peroxisome proliferator-activated receptor γ 
co-activator 1 α (PGC-1α) while simultaneously promoting an increased NAD+ to NADH 
ratio and activating sirtuin 1 (SIRT1). Nutritional compounds such as resveratrol (RSV) can 
also activate SIRT1 through this route, whereas NAD+ precursors, such as nicotinamide 
riboside (NR), might directly elevate NAD+ levels through catalysis by nicotinamide phos-
phoribosyltransferase (NAMPT) and promote SIRT1 activity. The downstream outcome of 
activating these pathways converges onto an improved mitochondrial phenotype by 
multiple routes.
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general population, as artificial light enables individuals 
to avoid adapting their lifestyle to the circadian clock 
and plan activities independent of the day–night cycle.
Interestingly, research in the past decade clearly indi-
cates that mitochondrial metabolism is under control 
of the biological clock and that peripheral tissues have 
their own rhythm, triggered by a cellular molecular clock. 
This molecular clock comprises closely intertwined 
transcriptional and post-translational negative feedback 
loops. Positive regulation of these feedback loops occurs 
via the transcription factors circadian locomoter output 
cycles protein kaput (CLOCK) and aryl hydrocarbon 
receptor nuclear translocator-like protein 1 (ARNTL, 
better known as BMAL1), which in turn activate the 
negative regulators cryptochrome-2 (CRY) and period 
circadian protein homologue 1 (PER)125. Downstream of 
BMAL1 is nuclear receptor subfamily 1 group D mem-
ber 1 (NR1D1, also known as Rev-erbA-α), an important 
nuclear receptor for lipid metabolism and adipogene-
sis126, which is also expressed in skeletal muscle where 
it seems to modulate the oxidative phenotype127 (FIG. 4). 
Output of this molecular clock in peripheral tissues is 
very sensitive to feeding–fasting cycles and the nutrient 
sensors AMPK and SIRT1 are regulated in a circadian 
manner to modulate the rhythm of metabolism optimally 
in anticipation of periods of activity or food intake128. In 
mice and rats, circadian misalignment leads to mitochon-
drial dysfunction129 and genetically or pharmacologically 
stimulating increased NR1D1 levels and activity results in 
an ‘athlete-like’ phenotype, with induced mitochondrial 
biogenesis, improved mitochondrial respiratory capac-
ity and increased running capacity127, factors commonly 
associated with improved insulin sensitivity. Intriguingly, 
upon liver-specific deletion of BMAL1 in a mouse model, 
liver mitochondria lose their capacity to adapt to altered 
nutrient availability, indicating a loss in metabolic flexi-
bility130, a phenomenon that was rescued by genetically 
inducing mitochondrial fission130. Hence, it is likely that 
disturbances in the molecular clock in peripheral tissues 
underlie the strong, albeit indirect, epidemiological 
indications by which sleep deprivation and disruption 
of circadian rhythm in humans negatively affect mito-
chondrial function and insulin sensitivity. However, 
studies examining the direct involvement of the molecu-
lar clock and its downstream targets in regulating mito-
chondrial function in humans are warranted before the 
molecular clock can be identified as a therapeutic target 
to promote insulin sensitivity via mitochondrial function.
Carnitine supplementation. As outlined earlier in the 
article, T2DM, but also prediabetes, is characterized by 
metabolic inflexibility. In mouse and rat studies, insulin 
resistance and metabolic inflexibility have been associ-
ated with changes in carnitine status131. Processes such 
as ageing and the consumption of a high-fat diet, both 
recognized inducers of insulin resistance and metabolic 
inflexibility, were found to compromise the availability of 
free carnitine in mice131, whereas supplementation with 
carnitine in mice fed high-fat diets completely restored 
insulin sensitivity131. In addition, beneficial effects of 
carnitine supplementation on insulin sensitivity and 
glucose tolerance have been reported in humans132. As 
outlined previously in this article, in the presence of 
ample free carnitine, the mitochondrial enzyme CrAT 
can maintain the conversion of carnitine and acetyl-CoA 
to acetylcarnitine, reducing acetyl-CoA levels even under 
conditions of substrate oversupply. In the 1960s, it was 
proposed that a high level of acetyl-CoA inhibits pyru-
vate dehydrogenase activity, thereby reducing glucose 
catabolism, which could contribute to the development 
of insulin resistance133. However, high acetyl-CoA levels 
might also operate as an acetyl donor for mitochondrial 
protein acetylation, which is emerging as an important 
mechanism of metabolic regulation and mitochondrial 
function. In fact, protein hyperacetylation has been 
associated with insulin resistance upon high-fat feeding 
in mice134 and ageing135 in rats. Mitochondrial matrix 
proteins were shown to be sensitive to nutrient-induced 
protein acetylation, which is enhanced in mice lacking 
CrAT, suggesting that carnitine metabolism might also be 
involved in regulation of mitochondrial protein acetyla-
tion136. Clearly, human intervention studies are needed to 
determine whether carnitine supplementation in patients 
can improve insulin sensitivity and mitochondrial func-
tion via attenuation of mitochondrial protein acetylation 
by stimulating acetylcarnitine synthesis.
Ambient temperature and cold exposure. The discovery 
of cold-inducible BAT in adult humans137 has resulted 
in a large number of patient and animal studies inves-
tigating whether activation of BAT could be considered 
as a therapeutic target to treat obesity and T2DM138,139. 
Animal data reveal that cold exposure can reverse fasting- 
induced insulin resistance140 and that the benefi-
cial effects of cold exposure on glucose homeostasis 
and insulin sensitivity are dependent on BAT mass141. 
Figure 4 | Circadian clock and mitochondrial function. The cellular clockwork 
orchestrates circadian rhythms through oscillations in the transcription and translation 
of circadian locomoter output cycles protein kaput (CLOCK) and aryl hydrocarbon 
receptor nuclear translocator-like protein 1 (better known as BMAL1), which affect the 
levels of the BMAL1–CLOCK heterodimer. The self-regulation of the cycle occurs by 
BMAL1–CLOCK-controlled induction of period circadian protein homologue 1 (PER) and 
cryptochrome-2 (CRY) protein expression, after which the PER–CRY heterodimer 
triggers CLOCK and BMAL1 degradation. Furthermore, sirtuin 1 (SIRT1) activation can 
enhance the activity of PER–CRY and inhibits the activity of BMAL1. The activity of this 
peripheral clock leads to the transcription of genes involved in energy metabolism, which 
might affect insulin sensitivity and mitochondrial function. 
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However, the relative contribution of BAT to whole-
body metabolism differs considerably between mice 
and humans. In fact, our group showed that 10 days 
of cold acclimation markedly promoted whole-body 
insulin sensitivity in patients who have T2DM, with an 
average increase in insulin sensitivity of ~43%142. Most 
remarkably, this increase in insulin sensitivity could not 
be explained by BAT activity, which only increased mar-
ginally. Rather, 10 days of cold acclimation resulted in a 
clear increase in GLUT-4 translocation to the cell surface 
in skeletal muscle, a finding that we also confirmed in 
patients with obesity143. So far, the underlying mecha-
nism for this effect has not been unravelled, but did not 
involve substantial improvements in skeletal muscle 
mitochondrial respiration capacity.
In mice, cold-induced nonshivering thermogenesis in 
skeletal muscle requires activation of sarcolipin144 (a pivo-
tal component of sarcoplasmic reticulum Ca2+–ATPase 
activity that is involved in mitochondrial bio genesis) and 
overexpression of this protein also increased fat oxida-
tive capacity and energy expenditure in these animals145. 
Although under normal physio logical conditions the 
energy needed for active Ca2+ transport is unlikely to 
exceed 10% of total muscle energy expenditure146, muscle 
energy expenditure might rise to 140% of normal con-
ditions when the Ca2+ transient is slightly elevated (sub- 
contraction depolarization of the sarcolemma)147. Notably, 
at this sub-contraction level of depolarization, muscle 
tension only increases by a mere 3%147. Human studies 
examining the role of Ca2+ transients in energy expend-
iture, mitochondrial function and insulin sensitivity in 
skeletal muscle are presently lacking. However, induction 
of futile cycling via Ca2+ transients, be it by cold exposure 
or by sub-threshold muscle contractions, could contrib-
ute to increased energy expenditure and improved insulin 
sensitivity, as observed in humans upon cold exposure142, 
fidgeting148 or during very mild exercise regimes such as 
strolling149 or breaking sitting time150. Clearly, future studies 
are needed to expand this exciting field of research.
Ambient temperature and heat stress. Intriguingly, in 
addition to the association between cold exposure and 
improvements in insulin sensitivity, heat stress has also 
been linked to altered glucose homeostasis. Upon 3 weeks 
of heat exposure in a hot tub (37–40 °C) for 30 min per 
day, fasting plasma glucose concentration and HbA1c lev-
els dropped substantially in five male and three female 
patients with T2DM151. A member of the family of heat 
responsive proteins known as heat shock proteins (HSPs), 
heat shock-related 70 kDa protein 2 (HSPA2), seems 
to be involved in the glucoregulatory potential of heat 
exposure. HSPA2 levels were lower in skeletal muscle 
biopsy samples from patients with T2DM than in non-
diabetic control individuals, with HSPA2 gene expres-
sion and protein content also found to correlate positively 
with insulin-stimulated glucose uptake152,153. More direct 
studies revealed that using heat stress, as well as phar-
macological and genetic approaches, to stimulate HSPA2 
expression all improved insulin sensitivity154. Moreover, 
heat-stress-mediated induction of HSPA2 in rats fed a 
high-fat diet alleviated insulin resistance, reduced mito-
chondrial dysfunction155 and improved both respiratory 
capacity and fat oxidative capacity155. Furthermore, 
induction of HSPA2 expression also induced mitochon-
drial biogenesis in an AMPK–SIRT1–PGC-1α dependent 
manner in cultured myotubes156.
A variety of small molecule activators and co-activators 
of HSPs seem to affect mitochondrial physiology157. 
Promisingly, one of these co-activators, a small molecule 
drug candidate named BGP-15, was proven to promote 
insulin sensitivity in nondiabetic individuals with insu-
lin resistance158. Although this study did not examine 
direct involvement of HSPA2 or mitochondrial adapta-
tions in the observed improvements in glucose handling, 
it seems fair to conclude that, in addition to cold expo-
sure, mild heat stress might also affect mitochondrial 
function and improve insulin sensitivity.
Conclusion and future perspectives
The association between mitochondrial function and 
insulin sensitivity has been well established and ample 
evidence exists that boosting mitochondrial function 
improves whole-body and skeletal muscle insulin sen-
sitivity and glucose homeostasis, at least in mice and 
rats. Albeit more limited in number than animal model 
studies, most human studies also provide compelling 
evidence that therapeutically targeting mitochondria 
to improve insulin sensitivity is a promising route. 
Importantly, mitochondria are central in the regulation 
of human cellular metabolism and cells relevant to meta-
bolic control are equipped with robust regulatory path-
ways enabling them to adapt mitochondrial metabolism 
to cellular conditions and demands. These findings 
identify mitochondria as targets for pharmacological or 
exercise interventions to treat T2DM, and also suggest 
that these organelles can be manipulated by lifestyle 
factors such as nutrition, environmental temperature 
and circadian rhythms. Despite the abundance of animal 
data, mechanistic human clinical intervention studies to 
target the diverse aspects of mitochondrial function in 
the treatment or prevention of T2DM are still limited, 
but urgently awaited.
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